Skip to Content

CSL focused on creating medical breakthroughs

Fri 24 August 2018 09:20 AM Stocks to watch

Recent articles

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

  • Data insights on how nabtrade customers are investing in CSL,
  • Why investors should focus on the company's research & development activities,
  • If CSL has an appetite for a stock split, and
  • The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack. 

Note: The article referred to in the video can be viewed here.

 

MTE_Macquarie_still

Macquarie CFO discusses profit forecast, strategy

Macquarie Group's Chief Financial Officer Alex Harvey discusses the company's recent results, its strategy under a new CEO and thinking around acquisitions.

14 November 2018 Stocks to watch
MTE-Boral-800x446-compressed

Boral CEO optimistic on infrastructure, dividend growth

Boral CEO Mike Kane discusses how the company is placed to capitalise on infrastructure spending in Australia and the United States, and his confidence in growing the firm’s dividend.

7 November 2018 Stocks to watch
Video_thumbnail_Afterpay

Afterpay gaining traction in U.S.

Afterpay Touch Group Head, David Hancock discusses the payments company’s growth strategy, competitive threats and focus on responsible spending.

4 September 2018 Stocks to watch
Video_Thumbnail

Santos CEO looks to growth, further cost reductions

Santos CEO Kevin Gallagher discusses the energy company’s growth strategy, continued focus on cost, dividends and LNG demand.

3 September 2018 Stocks to watch